Erica Lin1, Teng Moua2, Andrew H Limper3. 1. Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA. 2. Division of Pulmonary and Critical Care, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. moua.teng@mayo.edu. 3. Division of Pulmonary and Critical Care, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Abstract
PURPOSE: Mucormycosis encompasses a group of opportunistic fungal infections caused by Zygomycetes, order Mucorales. Mucormycosis can manifest as rhino-orbito-cerebral, pulmonary, gastrointestinal, cutaneous, and disseminated infections. Pulmonary mucormycosis is the second most common presentation. This manuscript characterizes the demographics, clinical presentation, diagnostic procedures, radiologic findings, therapeutic interventions, and outcome in pulmonary mucormycosis. METHODS: We retrospectively reviewed clinical data of 35 patients with pulmonary mucormycosis from 2000 to 2015. Microbiologic diagnosis was based on positive culture from a sterile site or findings on histopathology consistent with mucormycosis. Independent predictors of 28-day mortality were assessed using logistic regression. Survival curves were estimated using Kaplan-Meier method. RESULTS: There was male predominance with a mean age of 55 ± 15 years. Analysis of predisposing conditions revealed the prevailing presence of malignancy. Sixty-six percent of patients were receiving immunosuppressive agents. Common presenting clinical findings were fever, neutropenia, dyspnea, and cough. Radiologic findings included pleural effusion and nodules. All patients received medical therapy and 43% underwent additional surgical intervention. Twenty eight day mortality was 29% with concurrent bacteremia found as the sole independent predictor. Similar survival from pulmonary mucormycosis was noted over time. CONCLUSIONS: Pulmonary mucormycosis is an opportunistic angioinvasive fungal infection. Physicians must have a high level of suspicion in immunocompromised patients with fever and respiratory symptoms refractory to antibiotics. A low threshold should be had for performing an invasive procedure to gain reliable diagnosis, as early, aggressive medical and surgical interventions are needed for successful treatment.
PURPOSE:Mucormycosis encompasses a group of opportunistic fungal infections caused by Zygomycetes, order Mucorales. Mucormycosis can manifest as rhino-orbito-cerebral, pulmonary, gastrointestinal, cutaneous, and disseminated infections. Pulmonary mucormycosis is the second most common presentation. This manuscript characterizes the demographics, clinical presentation, diagnostic procedures, radiologic findings, therapeutic interventions, and outcome in pulmonary mucormycosis. METHODS: We retrospectively reviewed clinical data of 35 patients with pulmonary mucormycosis from 2000 to 2015. Microbiologic diagnosis was based on positive culture from a sterile site or findings on histopathology consistent with mucormycosis. Independent predictors of 28-day mortality were assessed using logistic regression. Survival curves were estimated using Kaplan-Meier method. RESULTS: There was male predominance with a mean age of 55 ± 15 years. Analysis of predisposing conditions revealed the prevailing presence of malignancy. Sixty-six percent of patients were receiving immunosuppressive agents. Common presenting clinical findings were fever, neutropenia, dyspnea, and cough. Radiologic findings included pleural effusion and nodules. All patients received medical therapy and 43% underwent additional surgical intervention. Twenty eight day mortality was 29% with concurrent bacteremia found as the sole independent predictor. Similar survival from pulmonary mucormycosis was noted over time. CONCLUSIONS:Pulmonary mucormycosis is an opportunistic angioinvasive fungal infection. Physicians must have a high level of suspicion in immunocompromised patients with fever and respiratory symptoms refractory to antibiotics. A low threshold should be had for performing an invasive procedure to gain reliable diagnosis, as early, aggressive medical and surgical interventions are needed for successful treatment.
Authors: R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare Journal: Antimicrob Agents Chemother Date: 2006-01 Impact factor: 5.191
Authors: Georgios Chamilos; Edith M Marom; Russell E Lewis; Michail S Lionakis; Dimitrios P Kontoyiannis Journal: Clin Infect Dis Date: 2005-05-24 Impact factor: 9.079
Authors: E Alvarez; D A Sutton; J Cano; A W Fothergill; A Stchigel; M G Rinaldi; J Guarro Journal: J Clin Microbiol Date: 2009-04-22 Impact factor: 5.948
Authors: O A Cornely; S Arikan-Akdagli; E Dannaoui; A H Groll; K Lagrou; A Chakrabarti; F Lanternier; L Pagano; A Skiada; M Akova; M C Arendrup; T Boekhout; A Chowdhary; M Cuenca-Estrella; T Freiberger; J Guinea; J Guarro; S de Hoog; W Hope; E Johnson; S Kathuria; M Lackner; C Lass-Flörl; O Lortholary; J F Meis; J Meletiadis; P Muñoz; M Richardson; E Roilides; A M Tortorano; A J Ullmann; A van Diepeningen; P Verweij; G Petrikkos Journal: Clin Microbiol Infect Date: 2014-04 Impact factor: 8.067